Thermo Scientific Lab Vision Retinoblastoma (Rb) Ab-1, Mouse Monoclonal Antibody
Provide accurate, reproducible results with the Thermo Scientific Retinoblastoma (Rb) Ab-1, Mouse Monoclonal Antibody.
Manufacturer: Thermo Scientific MS107B0
Provide accurate, reproducible results with the Thermo Scientific Retinoblastoma (Rb) Ab-1, Mouse Monoclonal Antibody.Rb is a tumor suppressor nuclear phosphoprotein capable of binding to DNA. It is phosphorylated on serine and threonine, but not on tyrosine residues. It forms a complex with SV40 large T antigen, adenovirus E1A, and human papilloma virus-16 E. Rb protein may act by regulating transcription and loss of its function leads to uncontrolled cell growth. Aberrations in the RB gene have been implicated in cancers of breast, colon, prostate, kidney, nasopharynx, and leukemia.
Host Species: Mouse
Clone: 1F8; same as Rb1
Species Reactivity: Human. Does not react with mouse and rat. Others not known.
Epitope: aa 703-722
Immunogen: Recombinant human Rb protein
Molecular Weight: 105kDa
Positive Control: Ls174T, HT29, HUVEC cells; Normal colon, Breast CA and colon CA
Cellular Localization: Nuclear Ab-1 specifically stains the nuclei of BT-20 cells and primary human foreskin fibroblast (HFF) cells. It reacts with hyperphosphorylated and un (under) phosphorylated form of Rb protein. It shows no cross reaction with p107 and p130.
- Immunohistochemistry (Formalin/paraffin)
- Western Blotting
- Immunoprecipitation (Native and denatured)
- Flow Cytometry
USA: RUO; Int'l: RUO
|Retinoblastoma (Rb) Ab-1|
|Biotinylated Ab with BSA and Azide|
|Flow Cytometry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot|
|1F8; same as Rb1|
|Recombinant human Rb protein|
|Cancer and Tumor Biology|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok